We are monitoring the impact of COVID-19 on MEA Leukemia Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 769
Share on
Share on

Middle East & Africa Leukemia Therapeutics Market Research Report - Segmented By Disease Condition, Diagnosis, Treatments, Drugs & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 769
Pages: 145

MEA Leukemia Therapeutics Market Size & Growth (2021 to 2026)

The size of the Leukemia Therapeutics market in the Middle-East and Africa has been estimated at USD 0.59 Billion in 2021 and is projected to reach USD 0.92 Billion by 2026, at a CAGR of 9.23% during the forecast period from 2021 to 2026. 

Leukemia is a type of cancer where abnormal white blood cells crowd the bone marrow and other organs such as the liver, spleen, and kidneys through blood and prevent its normal functions. It is commonly caused due to the high exposure to radiation, an unhealthy lifestyle, genetic factors, and environmental conditions. It is common in adults and is observed to progress with aging.

The factor that is driving the market for Leukemia Therapeutics in Middle-east and Africa is the simultaneous increase in increasing awareness about cancer treatments and drugs, along with increasing occurrence. Also, due to the increasing aging population, the market is driven, as the disease is common with aging.

But the market is feared to decline due to the high costs of treatment and drugs.

This research report on the MEA Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories

By Disease Condition:              

  • Chronic Lymphatic Leukemia           
  • Acute Lymphatic Leukemia              
  • Chronic Myeloid Leukemia               
  • Acute Myeloid Leukemia  

By Diagnosis:

  • CT scan     
  • Biopsy       
  • MRI            

By Treatments:

  • Chemotherapy      
  • Radiation therapy
  • Immunotherapy   
  • Surgery     
  • Targeted Therapy
  • Bone marrow transplant   
  • Stem Cell Therapy

By Drugs:

  • Gleevec    
  • Sapacitabine           
  • GA101       
  • Vasaroxine              
  • Tosedosat      

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.

Factors such as the rising prevalence of Leukemia, growing awareness of cancer screening programs, and raising awareness for healthcare among the population in developing nations of the region are making the companies penetrate into this market.

The leading companies leading in the MEA Leukemia Therapeutics market profiled in the report are F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods  

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Disease Condition                          

                             5.1.1 Chronic Lymphatic Leukemia         

                             5.1.2 Acute Lymphatic Leukemia             

                             5.1.3 Chronic Myeloid Leukemia             

                             5.1.4 Acute Myeloid Leukemia  

              5.2 By Diagnosis                           

                             5.2.1 CT scan    

                             5.2.2 Biopsy      

                             5.2.3 MRI          

              5.3 By Treatments                        

                             5.3.1 Chemotherapy     

                             5.3.2 Radiation therapy

                             5.3.3 Immunotherapy  

                             5.3.4 Surgery    

                             5.3.5 Targeted Therapy

                             5.3.6 Bone marrow transplant  

                             5.3.7 Stem Cell Therapy

              5.4 By Drugs                    

                             5.4.1 Gleevec    

                             5.4.2 Sapacitabine         

                             5.4.3 GA101      

                             5.4.4 Vasaroxine            

                             5.4.5 Tosedosat             

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 Middle-East                            

              6.3 Africa                         

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 F. Hoffmann-La Roche Ltd                 

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 GlaxoSmithKline Pharmaceuticals Limited                  

              9.3 Novartis International AG                  

              9.4 Bristol-Myers Squibb                          

              9.5 Eisai Co. Ltd              

              9.6 Biogen Idec               

              9.7 ERYtech Pharma                    

              9.8 Celgene Corporation                           

              9.9 Genmab A/S                           

              9.10 Cephalon Inc.                       

              9.11 Clavis Pharma                      

              9.12 Pfizer Inc.                

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Leukemia Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  2. Middle East & Africa Leukemia Therapeutics Market By Disease condition, From 2021 to 2026 (USD Billion)
  3. Middle East & Africa Cchronic Lymphatic Leukemia Market By Region, From 2021 to 2026 (USD Billion)
  4. Middle East & Africa Acute Lymphatic Leukemia Market By Region, From 2021 to 2026 (USD Billion)
  5. Middle East & Africa Chronic Myeloid Leukemia Market By Region, From 2021 to 2026 (USD Billion)
  6. Middle East & Africa Acute Myeloid Leukemia Market By Region, From 2021 to 2026 (USD Billion)
  7. Middle East & Africa Leukemia Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  8. Middle East & Africa Leukemia CT scan Market By Region, From 2021 to 2026 (USD Billion)
  9. Middle East & Africa Leukemia Biopsy Market By Region, From 2021 to 2026 (USD Billion)
  10. Middle East & Africa Leukemia MRI Market By Region, From 2021 to 2026 (USD Billion)
  11. Middle East & Africa Leukemia Therapeutics Market By Treatments, From 2021 to 2026 (USD Billion)
  12. Middle East & Africa Leukemia Chemotherapy Market By Region, From 2021 to 2026 (USD Billion)
  13. Middle East & Africa Leukemia Radiation Therapy Market By Region, From 2021 to 2026 (USD Billion)
  14. Middle East & Africa Leukemia Immunotherapy Market By Region, From 2021 to 2026 (USD Billion)
  15. Middle East & Africa Leukemia Surgery Market By Region, From 2021 to 2026 (USD Billion)
  16. Middle East & Africa Leukemia Targeted Therapy Market By Region, From 2021 to 2026 (USD Billion)
  17. Middle East & Africa Leukemia Bone marrow transplant Market By Region, From 2021 to 2026 (USD Billion)
  18. Middle East & Africa Leukemia Stem Cell Therapy Market By Region, From 2021 to 2026 (USD Billion)
  19. Middle East & Africa Leukemia Therapeutics Market By Drugs, From 2021 to 2026 (USD Billion)
  20. Middle East & Africa Leukemia Gleevec Market By Region, From 2021 to 2026 (USD Billion)
  21. Middle East & Africa Leukemia Sepecitabine Market By Region, From 2021 to 2026 (USD Billion)
  22. Middle East & Africa Leukemia GA101 Market By Region, From 2021 to 2026 (USD Billion)
  23. Middle East & Africa Leukemia Vasaroxine Market By Region, From 2021 to 2026 (USD Billion)
  24. Middle East & Africa Leukemia Tosedosat Market By Region, From 2021 to 2026 (USD Billion)
  25. Middle East Leukemia Therapeutics Market By Disease condition, From 2021 to 2026 (USD Billion)
  26. Middle East Leukemia Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  27. Middle East Leukemia Therapeutics Market By Treatments, From 2021 to 2026 (USD Billion)
  28. Middle East Leukemia Therapeutics Market By Drugs, From 2021 to 2026 (USD Billion)
  29. Africa Leukemia Therapeutics Market By Disease condition, From 2021 to 2026 (USD Billion)
  30. Africa Leukemia Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  31. Africa Leukemia Therapeutics Market By Treatments, From 2021 to 2026 (USD Billion)
  32. Africa Leukemia Therapeutics Market By Drugs, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample